Literature DB >> 33118769

Prescribing of opioids for chronic pain on reimbursable prescription.

Svetlana Skurtveit, Vidar Hjellvik, Solveig Sakshaug, Petter C Borchgrevink, Børge Myrlund Larsen, Thomas Clausen, Eva Skovlund, Emilie Elise Heggen, Marte Handal.   

Abstract

BACKGROUND: In 2008 the reimbursable prescription scheme was amended so that patients with severe, chronic pain could be prescribed opioids on reimbursable prescription. The purpose of this study was to investigate the prescribing of opioids on reimbursable prescription, the proportion of patients who started opioid treatment on reimbursable prescription who became long-term users, and the number of patients in 2018 who received higher dosages than the reimbursable prescription scheme permits. MATERIAL AND
METHOD: Data were retrieved from the Norwegian Prescription Registry. Persons aged 18 or over who were dispensed at least one opioid on reimbursable prescription for severe, chronic pain in the period 2008-2018, were included.
RESULTS: The number of patients who were prescribed opioids on reimbursable prescription increased during the study period, and in 2018 the number was 17 383. Of these, 331 (1.9 %) were prescribed more than 300 mg oral morphine equivalents per day. After nine years, 48 % of the patients who started with opioids in 2009 were still being prescribed opioids on reimbursable prescription.
INTERPRETATION: A high proportion of patients with severe, chronic pain who started with opioids on reimbursable prescription became long-term users. A number of patients received higher dosages than are recommended.

Entities:  

Year:  2020        PMID: 33118769     DOI: 10.4045/tidsskr.20.0153

Source DB:  PubMed          Journal:  Tidsskr Nor Laegeforen        ISSN: 0029-2001


  1 in total

1.  Injury Prevention and long-term Outcomes following Trauma-the IPOT project: a protocol for prospective nationwide registry-based studies in Norway.

Authors:  Jo Steinson Stenehjem; Olav Røise; Trond Nordseth; Thomas Clausen; Bård Natvig; Svetlana O Skurtveit; Torsten Eken; Thomas Kristiansen; Jon Michael Gran; Leiv Arne Rosseland
Journal:  BMJ Open       Date:  2021-05-18       Impact factor: 2.692

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.